Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling.
about
Improving biophysical properties of a bispecific antibody scaffold to aid developabilityImmunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and ProteinsIdentification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activityImmunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies.Methodologies for the isolation of alternative binders with improved clinical potentiality over conventional antibodies.The Potential of Anti-IgE in Food Allergy Therapy.Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.Blockade of peanut allergy with a novel Ara h 2-Fcγ fusion protein in mice.Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines.Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity.Immunoglobulin E receptor signaling and asthmaDual targeting strategies with bispecific antibodies.Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies.The future of biologics: applications for food allergy.Molecular targets on B-cells to prevent and treat antibody-mediated rejection in organ transplantation. Present and Future.Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies.LUZ-Y, a novel platform for the mammalian cell production of full-length IgG-bispecific antibodies.Structural basis of a novel heterodimeric Fc for bispecific antibody production.Production of bispecific antibodies in "knobs-into-holes" using a cell-free expression systemHeavy and light chain pairing of bivalent quadroma and knobs-into-holes antibodies analyzed by UHR-ESI-QTOF mass spectrometry.The making of bispecific antibodiesDevelopment of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity.LC-MS characterization and purity assessment of a prototype bispecific antibody.A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.Improved assembly of bispecific antibodies from knob and hole half-antibodies.Generation of human bispecific common light chain antibodies by combining animal immunization and yeast display.Development of a novel affinity chromatography resin for platform purification of bispecific antibodies with modified protein a binding avidity.FcγRII-binding Centyrins mediate agonism and antibody-dependent cellular phagocytosis when fused to an anti-OX40 antibody.Productive common light chain libraries yield diverse panels of high affinity bispecific antibodies.Bispecific antibodies in cancer immunotherapy.Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies
P2860
Q27679445-FDF705BB-0717-4209-9644-96FB731397E3Q28072319-C112596B-5F73-41A8-B6B2-76A2DDBAA7CAQ28487387-87E02E5B-99B9-43E1-8591-4D8B78F34189Q33781380-0F82E948-EE35-495F-90EE-EF6C39197B94Q34220190-D244833B-A3C9-40DB-8A26-FC4E84820775Q34532292-D8EE312F-663C-42C8-A5B7-BE9904B486AFQ36729822-580FA130-19B2-4575-9179-456E5B3CB9CBQ36837286-CE4AD107-6B63-4AFE-AA18-EE74B3F4B019Q37168393-78CE2C63-990A-45A3-8FA3-685676DE3B40Q37496563-FE041451-A6C6-4755-BD0A-BCAF941C5E70Q37907670-633E39E1-01DA-4788-9CD9-4EFE30109CA4Q37997559-090B32E0-6F03-4684-9E8A-3D5092B36953Q38038410-5CFF93A1-8E4D-431D-A181-C79BD190B755Q38348057-9BBBD663-91CB-413B-9ED4-F3A06E61D7EBQ38676578-8503DDA4-AB24-467A-8226-43E05FED6503Q39129373-DA4E33BD-AD2C-4396-9BC7-2B8D7F78609AQ39250618-B3F3B08D-2B60-4042-A06A-E95E34D7CC3FQ41612592-BDEBE526-3E5C-4EED-BD17-CEBE3E4D8FFDQ41647084-2F9BDFFC-7CBF-4A11-B5CC-CCBF70D20CF9Q41864920-DB18DB80-D626-4C76-9256-F019F8EABE21Q42323236-F5E9F570-CA8B-49FD-BB9F-6DF77BBDBF05Q42392973-0418A438-494C-4E49-AB8D-B3782CBBCF37Q42846236-6DEBF732-29DA-495D-86F2-F0A5CB3BC37AQ45882197-30451398-5A3D-4D34-95FB-CBF837C3D70BQ46711768-CA0F9B2A-B4DA-4D3D-95E4-1566311A42A9Q48877236-33209F84-E77C-452B-A7BB-3B31EAAC1939Q49718154-29A96D13-6970-4A0A-8A5F-80A6FF59D662Q49847008-F4C4756D-9C42-435E-89E8-8CC49CF118E3Q49951608-B7F11540-6089-4FDF-8B74-EE905EA57840Q51309023-988514A7-8BFC-4B59-8A49-ED5A55566E1BQ58724935-C02F1754-CB85-4A31-B7E6-1EFCEF45B137
P2860
Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Development of a two-part stra ...... hibits IgE receptor signaling.
@ast
Development of a two-part stra ...... hibits IgE receptor signaling.
@en
type
label
Development of a two-part stra ...... hibits IgE receptor signaling.
@ast
Development of a two-part stra ...... hibits IgE receptor signaling.
@en
prefLabel
Development of a two-part stra ...... hibits IgE receptor signaling.
@ast
Development of a two-part stra ...... hibits IgE receptor signaling.
@en
P2093
P2860
P356
P1476
Development of a two-part stra ...... hibits IgE receptor signaling.
@en
P2093
Arthur Huang
Barbara Moffat
Daniel G Yansura
Diana Wadley
Janet Jackman
Juan Zhang
Justin M Scheer
Lawren C Wu
Michele C Bauer
Nancy Chiang
P2860
P304
20850-20859
P356
10.1074/JBC.M110.113910
P407
P577
2010-05-05T00:00:00Z